Stock Scorecard



Stock Summary for MoonLake Immunotherapeutics - Class A (MLTX) - $41.91 as of 5/5/2025 8:39:54 PM EST

Total Score

9 out of 30

Safety Score

40 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for MLTX

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for MLTX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for MLTX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for MLTX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for MLTX (40 out of 100)

Stock Price Rating (Max of 10) 8
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for MLTX

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 4/25/2025 8:05:00 PM
MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates 4/3/2025 11:00:00 AM
This West Pharmaceutical Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Bloom Energy ( NYSE:BE ) , Alpha Cognition ( NASDAQ:ACOG ) 3/18/2025 3:36:00 PM
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 9/9/2024 11:00:00 AM
Autoinjectors Market Size to Hit USD 3.8 Billion Milestone by 2034 with 16.2% CAGR Growth | Exclusive Report by Transparency Market Research, Inc. 8/19/2024 11:25:00 AM
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis - MoonLake ( NASDAQ:MLTX ) 6/10/2024 12:00:00 PM
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update 5/7/2024 12:00:00 PM
MoonLake Jumps As It Looks To Take On AbbVie Blockbuster, Humira 3/11/2024 2:41:00 PM
Why Is MoonLake Immunotherapeutics Stock Trading Higher Today? - MoonLake ( NASDAQ:MLTX ) 3/11/2024 1:56:00 PM
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis ( PsA ) and other important updates at its R&D Day 3/10/2024 5:00:00 PM

Financial Details for MLTX

Company Overview

Ticker MLTX
Company Name MoonLake Immunotherapeutics - Class A
Country USA
Description N/A
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date 5/5/2025

Stock Price History

Last Day Price 41.91
Price 4 Years Ago 9.89
Last Day Price Updated 5/5/2025 8:39:54 PM EST
Last Day Volume 277,124
Average Daily Volume 483,799
52-Week High 58.26
52-Week Low 31.42
Last Price to 52 Week Low 33.39%

Valuation Measures

Trailing PE N/A
Industry PE 32.04
Sector PE 37.03
5-Year Average PE -29.66
Free Cash Flow Ratio 14.76
Industry Free Cash Flow Ratio 19.19
Sector Free Cash Flow Ratio 29.42
Current Ratio Most Recent Quarter 21.11
Total Cash Per Share 2.84
Book Value Per Share Most Recent Quarter 7.08
Price to Book Ratio 5.89
Industry Price to Book Ratio 7.60
Sector Price to Book Ratio 21.93
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 101.19
Sector Price to Sales Ratio Twelve Trailing Months 28.34
Analyst Buy Ratings 11
Analyst Strong Buy Ratings 4

Share Statistics

Total Shares Outstanding 63,474,000
Market Capitalization 2,660,195,340
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -335,054.64%
Reported EPS 12 Trailing Months -1.89
Reported EPS Past Year 0.00
Reported EPS Prior Year -1.89
Net Income Twelve Trailing Months -118,935,517
Net Income Past Year -120,680,002,000
Net Income Prior Year -36,007,260
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 180,426,449
Total Cash Past Year 180,426,449
Total Cash Prior Year 451,169,337
Net Cash Position Most Recent Quarter 180,426,449
Net Cash Position Past Year 180,426,449
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 446,825,002,000
Total Stockholder Equity Prior Year 495,675,683
Total Stockholder Equity Most Recent Quarter 446,825,002,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -116,587,782,525
Free Cash Flow Per Share Twelve Trailing Months -1,836.78
Free Cash Flow Past Year -116,587,782,517
Free Cash Flow Prior Year -43,062,801

Options

Put/Call Ratio 0.03
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.55
MACD Signal -0.07
20-Day Bollinger Lower Band 32.39
20-Day Bollinger Middle Band 43.15
20-Day Bollinger Upper Band 53.91
Beta 1.32
RSI 61.48
50-Day SMA 45.56
150-Day SMA 36.41
200-Day SMA 29.62

System

Modified 5/3/2025 5:06:42 AM EST